STOCK TITAN
  1. Home
  2. News
  3. MOTS

Motus GI Holdings Inc - MOTS STOCK NEWS

Welcome to our dedicated news page for Motus GI Holdings (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on Motus GI Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Motus GI Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Motus GI Holdings's position in the market.

News
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Motus GI Holdings, Inc. (MOTS) initiated a U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, leading to successful UGI procedures at top hospital systems. The Company aims to accelerate commercialization through strategic partnerships. An infusion of $2.7M from outstanding warrants extended the cash runway till Q4 2024. Financially, revenue declined from $109,000 in Q4 2022 to $64,000 in Q4 2023, with a net loss of $2.8 million. However, the Company reported $5.0 million in cash and cash equivalents as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.57%
Tags
earnings
-
News
EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer
Rhea-AI Summary
EndoSound appoints Scott Aldrich Jr as CEO, leveraging his expertise from MotusGI for EVS launch. The company aims for sustainable growth in the medical technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
management
-
News
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
Rhea-AI Summary
Motus GI Holdings, Inc. announced the immediate exercise of an outstanding Series B common stock purchase warrant, resulting in gross proceeds of approximately $2.7 million. The investor exercised the warrant at a revised price of $0.925 per share and received two new unregistered warrants. The transaction is expected to close by February 26, 2024, and the net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.18%
Tags
none
News
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Rhea-AI Summary
Motus GI Holdings, Inc. announces the issuance of a new patent by the USPTO for their Colon Cleaning System with Automatic Self-Purging Feature, aimed at improving endoscopic outcomes. The patent covers the automated pressure management and self-purging feature of the Pure-Vu system, enhancing physician experience by avoiding procedure delays. This innovation addresses common issues in inpatient endoscopy, reducing the need for delayed, aborted, and repeat procedures, ultimately benefiting both patients and the healthcare system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68.71%
Tags
none
-
News
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
Rhea-AI Summary
Motus GI Holdings, Inc. adjourned its special meeting of stockholders to allow more time for voting on a proposal outlined in the Proxy Statement filed with the SEC. The meeting will reconvene on March 7, 2024, with the original record date remaining unchanged. Stockholders are encouraged to vote 'FOR' the proposal, with previously submitted proxies still valid.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
Rhea-AI Summary
Motus GI Holdings, Inc. announced positive data from a study of the second generation Pure-Vu System in the United European Gastroenterology journal. The study showed improved bowel cleansing in patients with previous poor preparation, reducing the need for repeat colonoscopies and clinical admissions. The study met its primary and secondary endpoints, with a high rate of adequate cleansing and cecal intubation. The next generation Pure-Vu System, with FDA clearance, features key enhancements addressing limitations of the previous model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.73%
Tags
none
News
 Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
Rhea-AI Summary
Motus GI Holdings, Inc. (Nasdaq: MOTS) announced a public offering of 3,333,334 shares of common stock, Series A common warrants, and Series B common warrants at a combined public offering price of $1.50 per share, resulting in approximately $5.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.07%
Tags
offering
-
News
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) reported its financial results for Q3 2023, announcing the FDA clearance for the Pure-Vu® EVS Gastro and Gen 4 Colon system. The company aims to initiate broader market introductions by the end of 2023. The Pure-Vu EVS Gastro targets the Upper GI market, addressing high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. The company is exploring strategic and financing alternatives to accelerate commercialization of the Pure-Vu System and maximize stockholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.75%
Tags
earnings
-
News
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro
Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced the successful use of Pure-Vu EVS Gastro in the first procedure since FDA clearance, addressing the high unmet clinical need in the Upper GI market, with approximately 400,000 cases of upper GI bleeds per year in the U.S. The device provides enhanced irrigation and suction capabilities, targeting blood, blood clots, and other debris in the upper GI tract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
none
News
Motus GI Announces 1-for-15 Reverse Stock Split
Rhea-AI Summary
Motus GI Holdings, Inc. will effect a 1-for-15 reverse stock split of its outstanding common stock to increase the per share trading price and meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will result in every fifteen pre-split shares of common stock becoming one share, reducing the number of shares from approximately 8.7 million to approximately 0.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1023.14%
Tags
none
Stock MOTS logo
Motus GI Holdings Inc

Nasdaq:MOTS

MOTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MOTS Stock Data

1.37M
4.97M
1.12%
4.71%
0.45%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Fort Lauderdale

About MOTS

motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.